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1. INTRODUCTION {#cam41990-sec-0001}
===============

Lung cancer has been identified as the leading cause of cancer death for decades with a high incidence worldwide.[1](#cam41990-bib-0001){ref-type="ref"} Approximately 85% of lung cancer patients are diagnosed with non‐small cell lung cancer (NSCLC). Surgical resection, whenever possible, is generally the preferred treatment modality for early stage NSCLC.[2](#cam41990-bib-0002){ref-type="ref"}

Visceral pleural invasion (VPI) was determined as a negative prognosticator in NSCLC and was first incorporated into the fifth edition tumor, node, metastasis (TNM) staging criteria in 1997.[3](#cam41990-bib-0003){ref-type="ref"} The International Association for the Study of Lung Cancer (IASLC) recommended the classification of the status of VPI as follows: PL0, tumor grows within the parenchyma or does not completely penetrate the elastic layer; PL1, tumor extends beyond the elastic layer; PL2, tumor invades into the surface of the visceral pleura.[2](#cam41990-bib-0002){ref-type="ref"}, [4](#cam41990-bib-0004){ref-type="ref"} To sum up, PL0 indicates no evidence of VPI, while PL1 and PL2 both represent the invasion of visceral pleural. In the seventh and eighth edition of TNM staging system, VPI has been identified as a non‐size‐based T2 factor, upstaging tumors ≤3 cm to T2a. Previous studies demonstrated that patients with VPI correlated with a higher incidence of pleural effusion, mediastinal nodal metastasis and postoperative recurrence, emphasizing the significance of improving treatment strategies.[5](#cam41990-bib-0005){ref-type="ref"}, [6](#cam41990-bib-0006){ref-type="ref"}, [7](#cam41990-bib-0007){ref-type="ref"}

Adequate lymph nodes (LNs) assessment is associated with favorable prognosis and plays a crucial part in the accurate staging of NSCLC. Previous studies illustrated the phenomenon that survival rate improved as more LNs were dissected in surgically resected NSCLC.[8](#cam41990-bib-0008){ref-type="ref"}, [9](#cam41990-bib-0009){ref-type="ref"}, [10](#cam41990-bib-0010){ref-type="ref"}, [11](#cam41990-bib-0011){ref-type="ref"} For example, Liang and colleagues studied the relationship between the examined LNs count and survival in NSCLC and identified 16 examined LNs as the optimal cut‐off point for evaluating the quality and thoroughness of LNs dissection.[8](#cam41990-bib-0008){ref-type="ref"} Samayoa et al. confirmed that survival of surgically resected node‐negative NSCLC patients was closely associated with the thoroughness of lymphadenectomy and recommended that at least 10 LNs should be examined.[10](#cam41990-bib-0010){ref-type="ref"} As far as we know, none of those previous studies explored the impact of the status of VPI on the correlation between the extent of lymphadenectomy and survival in stage I NSCLC. The goal of our present study was to determine whether patients with T1‐sized/VPI tumors (stage IB) required more extensive LNs dissection to optimize survival than those with T1‐sized/non‐VPI tumors (stage IA), using a large population‐based database.

2. METHOD {#cam41990-sec-0002}
=========

2.1. Data collection {#cam41990-sec-0003}
--------------------

Research data were extracted from the Surveillance, Epidemiology, and End Results (SEER) program November 2017 update via SEER\*Stat software (National Cancer Institute, Bethesda, MD). In the past decades, SEER program progressively expanded from the previous nine registries to the current 18 registries covering approximately 28% of American population. From SEER database, all cases with microscopically confirmed NSCLC were selected. Patients who underwent pneumonectomy and those who underwent preoperative radiotherapy were excluded from this study. Histologic grade was reclassified as low grade (well differentiated and moderately differentiated) or high grade (poorly differentiated and undifferentiated). VPI status has been brought into SEER database since 2010 based on the data term, cs site‐specific factor 2. Thus, our study only included the patients who were diagnosed between 2010 and 2015. Furthermore, since the staging criteria of our study population were based on the seventh edition TNM staging criteria, patients were then reclassified according to the eighth edition TNM staging criteria. We only identified cases with pathologic T1‐2aN0M0 NSCLC owing to the possibility of invading adjacent structure or organ in T3‐4 stage. Our study also eliminated patients with T1‐sized tumors, but upstaged to T2a due to hilar atelectasis or obstructive pneumonia. Baseline demographics, cancer characteristics, and survival data were collected including ethnicity, marital status, sex, age of diagnosis, tumor grade and size, therapeutic method, number of LNs examined, death classification, and survival months. Since none of the protocols involved raw data collection and the patient data were anonymized and openly accessible, Institutional Review Board approval was not required.

2.2. Statistical analysis {#cam41990-sec-0004}
-------------------------

All statistical analysis was conducted on R version 3.5.1 (R foundation for statistical computing, Vienna, Austria) and SPSS version 22 (IBM Corp., Armonk, NY). To reduce disparities of baseline characteristics between the VPI group and non‐VPI group, we therefore conducted propensity score matching (PSM). Baseline characteristics (ethnicity, age, sex, tumor size, marital status, histologic type and grade) were incorporated in the propensity score analysis. *MatchIt* package in R was used to match patients in two groups by propensity scores with a 1:1 nearest neighbor matching. Lung cancer‐specific survival (LCSS), defined as the survival time from lung cancer diagnosis to death specific to lung cancer‐related death, was the primary outcome variable and was estimated with Kaplan‐Meier analyses. The difference in survival curves was determined by Log‐rank tests. Continuous variables were presented as mean ± SD and were compared using the Student *t* test, while categorical variables were expressed as frequency (percentage) and were measured with the Pearson chi‐squared test. Cox regression analyses were conducted to evaluate the impact of the number of examined LNs on survival, adjusted for other potential confounding clinicopathological factors. The optimal number of examined LNs was identified by analyzing the trend in hazard ratios (HR) calculated by multivariate Cox regression model, and the turning point in the HR curve was exactly the optimal examined LNs count. All statistical analyses were two‐sided, and a *P*‐value ≤0.05 was considered statistically significant.

3. RESULT {#cam41990-sec-0005}
=========

Our study finally identified 9297 NSCLC patients who met the inclusion criteria. Figure [1](#cam41990-fig-0001){ref-type="fig"} shows the data collection criteria of this study. In total, 1034 cases were diagnosed with VPI, including 586 patients with PL1 and 448 patients with PL2, while PL0 was identified in 8263 patients. Significant discrepancies in age, histologic type, race distribution, histologic grade, tumor size, and treatment modality were observed between the two cohorts (Table [1](#cam41990-tbl-0001){ref-type="table"}). Specifically, patients diagnosed with VPI were more likely to be older, to be diagnosed with adenocarcinoma, to have poor differentiation and larger tumors, and to complete adjuvant radiation, which indicated the imbalance in the baseline clinicopathological features between the unmatched groups. Therefore, we conducted PSM and 1034 pairs stratified by the status of VPI were successfully matched. The distribution of propensity scores before and after matching was shown in Figure [2](#cam41990-fig-0002){ref-type="fig"}.

![Study selection map](CAM4-8-669-g001){#cam41990-fig-0001}

###### 

Patients characteristics before and after matching

  Variable                  Before matching   After matching                                         
  ------------------------- ----------------- ---------------- --------- ------------- ------------- -------
  Age                       67.3 ± 9.1        68.0 ± 9.2       0.021     68.1 ± 9.2    68.0 ± 9.2    0.782
  Histologic type                                              \<0.001                               0.969
  Adenocarcinoma            6181 (74.8)       834 (80.7)                 836 (80.9)    834 (80.7)    
  Squamous cell carcinoma   2014 (24.4)       191 (18.4)                 190 (18.3)    191 (18.4)    
  Other                     68 (0.8)          9 (0.9)                    8 (0.8)       9 (0.9)       
  Sex                                                          0.205                                 0.332
  Female                    4742 (57.4)       572 (55.3)                 550 (53.2)    572 (55.3)    
  Male                      3521 (42.6)       462 (44.7)                 484 (46.8)    462 (44.7)    
  Race                                                         0.035                                 0.782
  Black                     689 (8.3)         103 (10.0)                 103 (10.0)    103 (10.0)    
  Other                     640 (7.8)         96 (9.3)                   87 (8.4)      96 (9.3)      
  White                     6934 (83.9)       835 (80.7)                 844 (81.6)    835 (80.7)    
  Marital status                                               0.574                                 0.687
  Married                   4791 (58.0)       609 (58.9)                 618 (59.8)    609 (58.9)    
  Unmarried                 3472 (42.0)       425 (41.1)                 416 (40.2)    425 (41.1)    
  Grade                                                        \<0.001                               0.442
  Low grade                 6224 (75.3)       717 (69.3)                 733 (70.9)    717 (69.3)    
  High grade                2039 (24.7)       317 (30.7)                 301 (29.1)    317 (30.7)    
  Tumor size(mm)            18.7 ± 6.2        20.9 ± 5.7       \<0.001   20.9 ± 5.9    20.9 ± 5.7    0.748
  Surgery                                                      0.534                                 0.295
  Lobectomy                 6825 (82.6)       846 (81.8)                 864 (83.6)    846 (81.8)    
  Sublobectomy              1438 (17.4)       188 (18.2)                 170 (16.4)    188 (18.2)    
  Number of examined LNs    9.4 ± 7.5         9.3 ± 7.5        0.765     9.4 ± 7.5     9.3 ± 7.5     0.711
  Adjuvant radiation                                           0.001                                 0.015
  No                        8156 (98.7)       1007 (97.4)                1022 (98.8)   1007 (97.4)   
  Yes                       107 (1.3)         27 (2.6)                   12 (1.2)      27 (2.6)      

VPI, visceral pleural invasion; LNs, lymph nodes.
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![Histograms demonstrating the distribution of propensity score before and after matching. VPI, visceral pleural invasion](CAM4-8-669-g002){#cam41990-fig-0002}

The Kaplan‐Meier curves revealed that patients with VPI had a decreased survival compared with those in the non‐VPI group (5‐year LCSS: 78.2% vs 85.1%; *P *=* *0.003; Figure [3](#cam41990-fig-0003){ref-type="fig"}A). Nevertheless, there was no significant difference in LCSS between PL1 and PL2. (5‐year LCSS 80.1% vs 75.7%; *P* = 0.385; Figure [3](#cam41990-fig-0003){ref-type="fig"}B). In regard to the treatment modality, we further analyzed the prognostic value of surgical extent and adjuvant radiotherapy in each group. Patients who underwent sublobectomy had slightly decreased survival than those who underwent lobectomy, but the difference is not statistically significant in either VPI group (5‐year LCSS 71.3% vs 79.8%; *P *=* *0.061; Figure [3](#cam41990-fig-0003){ref-type="fig"}C) or non‐VPI group (5‐year LCSS 79.8% vs 86.0%; *P *=* *0.797; Figure [3](#cam41990-fig-0003){ref-type="fig"}D). Unexpectedly, patients who received adjuvant radiotherapy had worse LCSS than those who underwent surgery alone in both VPI group (Figure [3](#cam41990-fig-0003){ref-type="fig"}E) and non‐VPI group (Figure [3](#cam41990-fig-0003){ref-type="fig"}F). Owing to limited number of cases in radiotherapy group and short follow‐up time, we could not precisely evaluate the therapeutic benefit of adjuvant radiotherapy.

![Survival curves stratified by (A) presence or absence of VPI, (B) depth of VPI, (C) resection scope in VPI group, (D) resection scope in non‐VPI group, (E) treatment modality in VPI group, and (F) treatment modality in non‐VPI group. VPI, visceral pleural invasion](CAM4-8-669-g003){#cam41990-fig-0003}

Cox regression models were conducted to estimate the adjusted HR depending on the examined LNs count. In the VPI group, examination of at least 11 LNs were significantly associated with survival benefit and patients with 14‐16 examined LNs had the lowest risk of death (HR, 0.439; 95% confidence intervals \[CI\], 0.233‐0.830; *P *=* *0.011; Figure [4](#cam41990-fig-0004){ref-type="fig"}A). By contrast, in patients without VPI, the risk of death sequentially decreased as more LNs were examined until a maximal survival benefit was reached with examination of 7‐8 LNs (HR, 0.519; 95% CI, 0.297‐0.906; *P *=* *0.021); however, the sequential improvement in survival was not statistically significant after examination of more than 10 LNs (Figure [4](#cam41990-fig-0004){ref-type="fig"}B). Kaplan‐Meier curves also demonstrated superior survival benefits in VPI group with 14‐16 retrieved LNs (Figure [4](#cam41990-fig-0004){ref-type="fig"}C) and non‐VPI group with 7‐8 retrieved LNs (Figure [4](#cam41990-fig-0004){ref-type="fig"}D). In the multivariate analysis, homogeneous prognostic factors for the VPI group and non‐VPI group included examined LNs count, tumor size, and tumor grade, whereas age was solely significant in the VPI group (Table [2](#cam41990-tbl-0002){ref-type="table"}, [3](#cam41990-tbl-0003){ref-type="table"}).

![The variance of Hazard Ratio with 95% confidence interval among different examined LNs count in VPI group (A) and non‐VPI group (B), with the green dot indicating the optimal cut‐point. Survival curves of patients stratified by the examined LNs count in VPI group (C) and non‐VPI group (D). VPI, visceral pleural invasion; LNs, lymph nodes](CAM4-8-669-g004){#cam41990-fig-0004}

###### 

Cox regression analysis of prognostic factors in T1‐sized/VPI tumors (stage IB)

  Variable                  Univariate            Multivariate                         
  ------------------------- --------------------- -------------- --------------------- -------
  Age                       1.031 (1.011‐1.052)   0.003          1.025 (1.004‐1.046)   0.021
  Histologic type                                                                      
  Adenocarcinoma            Reference                                                  
  Squamous cell carcinoma   1.471 (0.973‐2.225)   0.067                                
  Other                     2.098 (0.519‐8.595)   0.296                                
  Sex                                                                                  
  Female                    Reference                                                  
  Male                      1.171 (0.820‐1.675)   0.385                                
  Race                                                                                 
  Black                     Reference                                                  
  Other                     1.257 (0.522‐3.022)   0.610                                
  White                     1.223 (0.593‐2.342)   0.544                                
  Marital status                                                                       
  Married                   Reference                                                  
  Unmarried                 1.335 (0.934‐1.909)   0.113                                
  Grade                                                                                
  Low grade                 Reference                            Reference             
  High grade                1.812 (1.261‐2.603)   0.001          1.773 (1.226‐2.565)   0.002
  Tumor size(mm)            1.040 (1.007‐1.074)   0.017          1.031 (0.998‐1.065)   0.070
  Surgery                                                                              
  Lobectomy                 Reference                                                  
  Sublobectomy              1.500 (0.977‐2.303)   0.063                                
  Examined LNs count                                                                   
  1‐2                       Reference                            Reference             
  3‐4                       0.980 (0.588‐1.634)   0.938          1.019 (0.611‐1.701)   0.942
  5‐6                       0.921 (0.545‐1.555)   0.757          0.955 (0.565‐1.615)   0.865
  7‐8                       0.672 (0.425‐1.108)   0.153          0.708 (0.444‐1.174)   0.166
  9‐10                      0.608 (0.340‐1.090)   0.095          0.614 (0.341‐1.106)   0.104
  11‐13                     0.562 (0.328‐0.965)   0.037          0.579 (0.337‐0.994)   0.048
  14‐16                     0.428 (0.241‐0.772)   0.004          0.439 (0.233‐0.830)   0.011
  17‐19                     0.471 (0.258‐0.861)   0.006          0.490 (0.268‐0.896)   0.021
  ≥20                       0.505 (0.308‐0.909)   0.031          0.524 (0.331‐0.924)   0.041
  Extend of VPI                                                                        
  PL1                       Reference                                                  
  PL2                       1.172 (0.819‐1.676)   0.386                                
  Adjuvant radiation                                                                   
  No                        Reference                                                  
  Yes                       1.917 (0.893‐4.112)   0.095                                

HR, hazard ratio; CI, confidence interval; VPI, visceral pleural invasion; LNs, lymph nodes.
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###### 

Cox regression analysis of prognostic factors in T1‐sized/non‐VPI tumors (stage IA)

  Variable                  Univariate            Multivariate                         
  ------------------------- --------------------- -------------- --------------------- -------
  Age                       1.028 (0.976‐1.072)   0.104                                
  Histologic type                                                                      
  Adenocarcinoma            Reference                                                  
  Squamous cell carcinoma   1.610 (1.369‐1.893)   0.094                                
  Other                     1.415 (0.203‐8.847)   0.346                                
  Sex                                                                                  
  Female                    Reference                                                  
  Male                      1.055 (0.680‐1.637)   0.811                                
  Race                                                                                 
  Black                     Reference                                                  
  Other                     0.234 (0.052‐1.046)   0.057                                
  White                     0.730 (0.395‐1.352)   0.317                                
  Marital status                                                                       
  Married                   Reference                                                  
  Unmarried                 1.178 (0.759‐1.828)   0.466                                
  Grade                                                                                
  Low grade                 Reference                            Reference             
  High grade                1.756 (1.127‐2.737)   0.013          1.728 (1.105‐2.701)   0.016
  Tumor size (mm)           1.053 (1.013‐1.094)   0.009          1.058 (1.018‐1.100)   0.004
  Surgery                                                                              
  Lobectomy                 Reference                                                  
  Sublobectomy              0.920 (0.486‐1.740)   0.797                                
  Examined LNs count                                                                   
  1‐2                       Reference                            Reference             
  3‐4                       0.780 (0.443‐1.372)   0.389          0.796 (0.452‐1.400)   0.427
  5‐6                       0.513 (0.285‐0.921)   0.025          0.556 (0.309‐0.968)   0.042
  7‐8                       0.492 (0.282‐0.858)   0.012          0.519 (0.297‐0.906)   0.021
  9‐10                      0.505 (0.281‐0.907)   0.022          0.529 (0.294‐0.950)   0.033
  11‐13                     0.623 (0.366‐1.061)   0.081          0.638 (0.374‐1.086)   0.098
  14‐16                     0.702 (0.416‐1.151)   0.164          0.716 (0.522‐1.254)   0.194
  17‐19                     0.716 (0.439‐1.169)   0.182          0.759 (0.464‐1.240)   0.271
  ≥20                       0.805 (0.479‐1.354)   0.414          0.827 (0.488‐1.371)   0.476
  Adjuvant radiation                                                                   
  No                        Reference                                                  
  Yes                       1.751 (0.430‐7.128)   0.434                                

HR, hazard ratio; CI, confidence interval; VPI, visceral pleural invasion; LNs, lymph nodes.

John Wiley & Sons, Ltd

4. DISCUSSION {#cam41990-sec-0006}
=============

Although surgical resection confers significant therapeutic benefit and remains the first choice of treatment, the optimal extent of LNs evaluation for early stage NSCLC patients without any signs of LNs metastasis or distant disease is still under debate. Consistent with previous research,[8](#cam41990-bib-0008){ref-type="ref"}, [9](#cam41990-bib-0009){ref-type="ref"}, [10](#cam41990-bib-0010){ref-type="ref"}, [11](#cam41990-bib-0011){ref-type="ref"}, [12](#cam41990-bib-0012){ref-type="ref"}, [13](#cam41990-bib-0013){ref-type="ref"}, [14](#cam41990-bib-0014){ref-type="ref"} our study revealed the association of the examined LNs count with survival. Furthermore, we also have confirmed that the correlation between the extensiveness of LNs dissection and prognosis is dependent on VPI status, with T1‐sized/VPI tumors (stage IB) requiring a more extensive LNs dissection (14‐16 LNs) while T1‐sized/non‐VPI tumors (stage IA) requiring a less extensive LNs dissection (7‐8 LNs).

Since previous research which also investigated the optimal examined LNs count did not consider tumor size and VPI status, their findings were not applicable for all‐comers and thoracic surgeons could not handle all patients in the same way. The interaction of VPI status and the optimal examined LNs count could provide guidance on the management and treatment of early stage NSCLC. Deng et al. comprehensively investigated predictors of VPI in patients with T1‐sized NSCLC and identified older age, adenocarcinoma, poor differentiation, pleural indentation, and shorter distance from tumor edge to visceral pleural as significant risk factors of VPI.[15](#cam41990-bib-0015){ref-type="ref"} In clinic, when preoperative general examination revealed risk factors of VPI or intraoperative exploration suspected the diagnosis of VPI, surgeons were advised to perform a more extensive lymphadenectomy to optimize the survival benefit.

The impact of the examined LNs count on survival could be attributed to several underlying reasons. On the one hand, logic suggested that removal of more LNs would increase the likelihood of detecting metastatic LNs and contribute to improved nodal staging accuracy. A less extensive lymphadenectomy, however, conferred increased risk of omitting undiscovered metastatic LNs. Some patients with fewer examined LNs and declared N0 disease may actually have node‐positive disease and this group of patients was less likely to receive proper adjuvant therapy due to understaging (e.g., misdiagnosis of patients with nodal metastasis as N0 disease). Considering patients in VPI group had a higher incidence of LNs metastasis,[5](#cam41990-bib-0005){ref-type="ref"}, [16](#cam41990-bib-0016){ref-type="ref"}, [17](#cam41990-bib-0017){ref-type="ref"} we hence speculated that a greater number of undiscovered metastatic LNs existed in VPI group with declared N0 disease. Thus, more extensive LNs examination was recommended for patients with VPI to improve staging accuracy and the chance of cure. On the other hand, more extensive LNs examination reflected not only surgeon\'s proficiency in LNs dissection but also pathologist\'s technique in LNs examination, and thus could potentially affect surgical outcomes. As described in a previous study, exquisite operative technique and remarkable patient care provided by high‐volume medical center may improve prognosis of early stage NSCLC patients.[18](#cam41990-bib-0018){ref-type="ref"} In addition, as filters for cancer cells and foreign bodies, LNs are critical component of human immune system. The negative LNs count also might reflect the intensity of anticancer immune response, which would influence survival.[19](#cam41990-bib-0019){ref-type="ref"}

The negative prognostic effect of VPI in surgically resected NSCLC has been well‐defined. Nevertheless, the prognostic significance of the depth of VPI (PL1 vs PL2) was still under debate. In this study, VPI was correlated with a significant decreased survival, but there was no significant difference in survival rate between PL1 and PL2. Consistent with our results, Adachi et al. demonstrated that presence of VPI, instead of the depth, was correlated with postoperative survival.[5](#cam41990-bib-0005){ref-type="ref"} In contrast, hung and colleagues identified PL2 as an indicator of worse survival and frequent recurrence in node‐negative NSCLC.[6](#cam41990-bib-0006){ref-type="ref"} A recent meta‐analysis conducted by Wang et al. also confirmed that the survival of PL1 patients was superior to that of PL2 patients.[17](#cam41990-bib-0017){ref-type="ref"} Although the eighth TNM staging system did not incorporate the extent of VPI into T descriptor, the IASLC did indicate that PL2 had a wore prognosis.[20](#cam41990-bib-0020){ref-type="ref"} Therefore, additional prospective studies were warranted to clarify the prognostic significance of the depth of VPI in early stage NSCLC patients.

The optimal resection scope of stage I NSCLC is still under debate and the optimal treatment modality for patients with VPI remains unclear. Moon and colleagues studied the surgical outcomes of 271 NSCLC patients with angiolymphatic or visceral pleural invasion and revealed that survival rate did not differ significantly by surgical extent, but their study did not distinguish VPI from angiolymphatic invasion and was based on a small sample size.[21](#cam41990-bib-0021){ref-type="ref"} A recent PSM study designed by Subramanian et al. identified that sublobar resection groups could acquire identical survival benefit as lobectomy groups in stage I NSCLC.[22](#cam41990-bib-0022){ref-type="ref"} On the contrary, two published meta‐analysis declared a significant worse survival in limited resection group.[23](#cam41990-bib-0023){ref-type="ref"}, [24](#cam41990-bib-0024){ref-type="ref"} In this study, although the extent of resection did not significantly correlate with LCSS in both VPI group and non‐VPI group, patients who underwent sublobectomy had slightly decreased survival than those who underwent lobectomy. And at the same time, it is worth noting that the survival curves stratified by the extent of resection almost clustered together in T1‐sized/non‐VPI tumors (stage IA), but well‐separated in T1‐sized/VPI tumors (stage IB) without superposition. Besides, in Cox regression models, limited resection of T1‐sized/VPI tumors (stage IB) correlated with increased mortality risk (HR = 1.500), while the HR for T1‐sized/non‐VPI tumors (stage IA) undergoing limited resection was close to 1 (HR = 0.920). Moreover, the *P*‐value of log‐rank test (*P *=* *0.061) and univariate Cox regression analysis (*P *=* *0.063) concerning the association of surgical approach with survival in VPI group was close to the threshold (0.05). Nevertheless, the limited number of cases in the sublobar resection group and relatively short follow‐up time of our study cohort restricted us to perform detailed analysis of optimal extent of surgical resection for stage I NSCLC stratified by tumor size and VPI status. Given the above analysis, we recommend active follow‐up for T1‐sized/VPI tumors (stage IB) after sublobar resection. The benefit of performing lobectomy in the VPI group could be attributed to the greater chance of radical dissection of involved visceral pleural and lymphatic vessels. Previous studies showed that adjuvant radiation failed to confer survival benefit for early stage NSCLC, but none of those studies incorporated VPI status.[25](#cam41990-bib-0025){ref-type="ref"}, [26](#cam41990-bib-0026){ref-type="ref"} In this study, patients with VPI had a higher likelihood of receiving adjuvant radiotherapy. However, the therapeutic benefit of adjuvant radiotherapy could not be precisely measured owing to relatively small number of radiated patients.

This population‐based study also has several limitations, including constraint of SEER database and the retrospective nature. First, the protocol for dissecting and examination of LNs may vary among different medical centers and the expertise of surgeons and pathologists was unknown, which could affect the quality of LNs dissection. Second, although the SEER registry provided information about examined LNs count, the number of examined LNs station, which is free from the risk of being confounded by fragmentation of LNs, was not recorded. However, in spite of the risk of being confounded by the fragmentation, the examined LNs count remains an appropriate surrogate for the thoroughness in LNs examination. Moreover, data on comorbidities, complications, chemotherapy, pulmonary function, and surgical margin were not available, which could cause potential bias.

In conclusion, this study demonstrates that the extent of LNs examination required to optimize survival differs based on VPI status in stage I NSCLC, with T1‐sized/VPI tumors (stage IB) requiring a more extensive LNs examination than T1‐sized/non‐VPI tumors (stage IA).
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